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Pancreatic and duodenal homeobox 1 (PDX1) regulates pancreatic development and mature b-cell func-
tion. We demonstrate by mass spectrometry that serine residue at position 269 in the C-terminal domain
of PDX1 is phosphorylated in b-cells. Besides we show that the degree of phosphorylation, assessed with
a phospho-Ser-269-speciﬁc antibody, is decreased by elevated glucose concentrations in both MIN6 b-
cells and primary mouse pancreatic islets. Homeodomain interacting protein kinase 2 (HIPK2) phosphor-
ylates PDX1 in vitro; phosphate incorporation substantially decreases in PDX1 S269A mutant. Silencing of
HIPK2 led to a 51 ± 0.2% decrease in Ser-269 phosphorylation in MIN6 b-cells. Mutation of Ser-269 to
phosphomimetic residue glutamic acid (S269E) or de-phosphomimetic residue alanine (S269A) exerted
no effect on PDX1 half-life. Instead, PDX1 S269E mutant displayed abnormal changes in subnuclear local-
ization in response to high glucose. Our results suggest that HIPK2-mediated phosphorylation of PDX1 at
Ser-269 might be a regulatory mechanism connecting signals generated by changes in extracellular glu-
cose concentration to downstream effectors via changes in subnuclear localization of PDX1, thereby inﬂu-
encing islet cell differentiation and function.
 2010 Elsevier Inc. Open access under CC BY license.1. Introduction
Control by glucose of preproinsulin gene transcription in pan-
creatic islet b-cells involves the interplay of multiple trans- and
cis-activating factors ([1] and references therein). Pancreatic and
duodenal homeobox 1 (PDX1) was ﬁrst described as a preproinsu-
lin promoter A3-site binding factor [2,3]. PDX1 is involved in both
the development and function of pancreatic b and other islet cells
[4].
Deletion or inactivation of the PDX1 gene in the mouse [5] or in
man [6] results in the complete failure of normal pancreatic devel-
opment. Moreover, b-cell selective disruption of murine PDX1
expression [7] or function [8] lead respectively to defective insulin
secretion and glucose signaling. On the other hand, heterozygosity
for a defective PDX1 gene leads to defective preproinsulin gene
expression [7] and abnormal insulin secretion [9] in mice and to
maturity-onset-diabetes of the young 4 (MODY4) in man [6].
In contrast to the relatively well-studied functions of the N-ter-
minus and the homeodomain of PDX1, the role of the conservedMedicine, Imperial College
44 020 7594 3351.
r).
cribed in this manuscript.
Y license.C-terminus is less well deﬁned.Mutationswhich affect the C-termi-
nus of PDX1 are associated with the development of type 2 diabetes
inhumans [10–12],while otherﬁndings indicate that theC-terminal
domainmay serve as both repressor and activator of PDX1 function
[13,14].
Humphrey and colleagues [15] reported that PDX1 phosphoryla-
tion in primary rat islets is decreased by high glucose levels. These
authors described Ser-268 and Ser-272 of rat PDX1 (corresponding
to Ser-269 and Ser-273 of mouse PDX1) as a novel C-terminal atyp-
ical non-primed GSK-3 consensus site which regulates PDX1 pro-
tein stability in response to glucose. Importantly, homeodomain
interacting protein kinase 2 (HIPK2) ([16] and references therein)
has been shown to co-localize with PDX1 in both the developing
and adult pancreas and tomodulate positively PDX1 transcriptional
activity, possibly by phosphorylation of the C-terminal domain
[17]. We have previously observed that, in clonal b-cells, elevated
glucose concentrations lead to translocation of PDX1 between the
nuclear periphery and the nucleoplasm, accompanied by increased
preproinsulin promoter activity [18]. Although the molecular basis
for the enhanced nucleoplasmic accumulation of PDX1 is unclear,
this process may involve interaction of PDX1 homeodomain with
the nuclear import receptor family member importin-b1 [19]. In
the present study we used mass spectrometry and generated an
anti-phospho-serine-speciﬁc antibody to conﬁrm Ser-269 as a bona
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cose in MIN6 b-cells and in primary mouse islets of Langerhans.
We show that Ser-269 is phosphorylated by homeodomain inter-
acting protein kinase 2 (HIPK2) in vitro. The analysis of (de)pho-
spho-Ser-269-speciﬁc mutants suggest that phosphorylation at
this site, whilst having no effect on PDX1 protein stability or
PDX1 DNA-binding property, is involved in nucleoplasmic (versus
nuclear-peripheric) localization in the b-cell in response to glucose.2. Materials and methods
The work described in this article has been carried out in accor-
dance with the EC Directive 86/609/EEC for animal experiments
http://europa.eu.int/scadplus/leg/en/s23000.htm; and the Uniform
Requirements for manuscripts submitted to Biomedical journals
http://www.nejm.org/general/text/requirements/1.htm.
2.1. Cell culture and reagents
Human embryonic kidney (HEK) 293 cells were cultured in Dul-
becco’s modiﬁed Eagle’s medium (DMEM) (Lonza) containing 10%
(v/v) fetal bovine serum (FBS), 100 IU/ml penicillin and 100 IU/ml
streptomycin. INS-1(832/13) cells (kindly provided by Dr. C. New-
gard, Duke University) and MIN6 b (mouse insulinoma pancreatic
beta) cells were cultured as in [20].
Anti-c-myc antibody was from Roche. Rabbit polyclonal anti-
PDX1 antibody was as described [18]. Anti-phospho-Ser-269-PDX1
antibodywas raised in rabbits by immunizationwith synthetic phos-
pho-peptide: L262PSGLSVpSPQPSSIAPLRPQEPR284 (Paciﬁc Immunol-
ogy Inc, USA). HIPK2 was purchased from Upstate (Lake Placid, NY).
2.2. Mouse islet isolation and culture
Islets were isolated from CD1 mice and cultured as previously
described [21].
2.3. Plasmids
Plasmid pcDNA3-PDX1-c-myc has been described [18]. Mutant
plasmids pcDNA3-PDX1-S269A-c-myc and pcDNA3-PDX1-S269E-c-
myc were generated using a QuikChange site-directed mutagenesis
kit (Stratagene). Wild-type and mutant PDX1 myc-tagged coding
sequences were inserted (HindIII/EcoRV) into the shuttle vector pAd-
Track-CMV multiple cloning site [22]. Mouse wild-type PDX1 se-
quence PCR ampliﬁed from plasmid pcDNA3-PDX1-c-myc was
cloned (NcoI/BamHI) into 6xHis-MBP (maltose binding protein) plas-
mid.Mutant plasmidHis-MBP-PDX1 (S269A)wasgenerated as above.
2.4. His-MBP-PDX1 production and puriﬁcation
His-MBP-PDX1 proteins expression was induced in Escherichia
coli BL21 with 0.2 mM isopropyl-b-D-thiogalactopyranoside (IPTG).
Proteins were puriﬁed on a nickel–nitrilotriacetic acid column
according to Qiagen and dialyzed for 16 h at 4 C in 50 mM Tris
pH 7.9, 150 mM NaCl, 5 mM MgCl2, 1 mM b-mercaptoethanol.
The MBP moiety was cut with Tobacco Etch Virus (TEV) protease,
AcTEVTM protease (Invitrogen). MBP, histidine tag and histidine-
tagged Ac-TEV protease were removed respectively with Amylose
beads (New England BioLab) and Ni–NTA agarose beads.
2.5. Recombinant adenoviruses and viral infection
Recombinant adenoviruses expressing wild-type (WT) and mu-
tant (S269A, S269E) PDX1 and control adenovirus, expressing
green ﬂuorescent protein (Ad-GFP) were prepared using theAdEasy system [22]. Cells were infected with various adenoviruses
at a multiplicity of infection (MOI) of 50 for 5 h and maintained in
25 mM glucose for 24 h before subsequent experiments.
2.6. Real-time RT-PCR
Total mRNA and real-time quantitative RT-PCR analysis was as
[23]. Primer sequences are as follows: cyclophilin A fwd, 50-TAT
CTG CAC TGC CAA GAC TGA-30; cyclophilin A rev, 50-CCA CAA TGC
TCA TGC CTT CTT TCA-30; HIPK2 fwd, 50-TGC TTG ACT TCC CCC
ATA GTG -30; HIPK2 rev, 50-CTT GCA AAT CTC CAT GTT TTG G -30.
Data were analyzed by ABR PRISM SDS v1.3.1 (Applied
Biosystems).
2.7. Immunocytochemistry
MIN6 b-cells infected with wild-type or mutant forms of PDX1
viruses at 50 MOI (multiplicity of infection). Immunocytochemical
analysiswas performed as described in the ﬁgure legends and in [20].
2.8. Immunoprecipitation
Cells lyzed on ice with 750 ll of IP buffer [1% (v/v) NP40 (Non-
idet P40); 50 mM NaCl; 1% (w/v) sodium deoxycholate; 0.1% (w/v)
sodium monododecyl sulfate (SDS); 50 mM Tris–HCl pH 7.5; 2 mM
EDTA; 10 mM sodium phosphate; 50 mM NaF (sodium ﬂuoride);
1 m PMSF; 200 lM Na3VO4 (sodium orthovanadate); 1  Com-
pleteTM protease inhibitor cocktail solution (Roche) and 1  phos-
phatase inhibitor cocktail 1 & 2 (Sigma)] were rotated on wheel
at 4 C for 30 min. The lysate was clariﬁed by centrifugation at
16,000g for 5 min. c-myc antibody-conjugated beads (Santa-Cruz;
40 ll) were added and tubes rotated at 4 C overnight. After centri-
fugation at 1,000g at 4 C for 30 s, beads were washed ﬁve times
with lysis buffer.
2.9. In vitro phosphorylation by HIPK2
Puriﬁed wild-type (WT) or serine to alanine mutant (S269A)
PDX1 (2 lg) was subjected to in vitro phosphorylation with HIPK2
(Upstate) following the manufacturer’s instruction.
2.10. Western blotting
Nuclear proteins were extracted as in [24]. Protein samples
were separated on SDS–PAGE, and analyzed by Western blotting
with the indicated antibodies.
2.11. Silencing of HIPK2
siRNA were made with the AMBION Silencer siRNA construction
kit. Starting primer pairswere designed as suggested in the AMBION
protocol andaccording to theguidelinespublished in [25]. Senseand
anti-sense primers were derived from mouse cDNA sequence for
HIPK2 in the ENSEMBL database (transcript name: Hipk2-201; tran-
script Id: ENSMUST00000038777). Target sequencewas fromnucle-
otide 788 to nucleotide 808 as follows: 50-AAA CGG GGC ACC AAT
GAAATT CCTGTC TC-30). Control siRNAweremadewith primers de-
rived by scrambling the siRNA sequence for HIPK2. All sequences
were searched against known mouse cDNA sequences using BLAST
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). Transfection was with
TransIT-TKO transfection reagent (Mirus Bio Corporation).
2.12. Pulse-chase
MIN6 b-cells were infected with PDX1 wild-type, S269A and
S269E adenoviruses. 24 h after infection, media were replaced with
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16 h. Cells were transferred for 1 h to cysteine/methionine-free
medium, pulsed for 3 h with 0.6 mCi [35S]cysteine/methionine
(Perkin–Elmer), after which cells were washed and cultured for
2, 4, 8, and 16 h in 5 ml chase media with 10,000-fold molar excess
of cold L-cysteine, L-methionine or harvested as the zero time point.
Cells were lyzed in 1 ml RIPA [50 mM Tris (pH 7.5), 150 mM NaCl,
1% (v/v) Nonidet P-40 (NP-40) 0.5% (w/v) sodium deoxycholate
(DOC), 0.1% (v/v) SDS, 0.4 mg/ml AESBF {4-(2-Aminoethyl) ben-
zenesulfonyl ﬂuoride hydrochloride}, 10 lg/ml Leupeptin, 10 lg/
ml Pepstatin, 5 lg/ml Aprotinin, 1  CompleteTM (Roche) and
1  phosphatase inhibitor cocktail 1 and 2 (Sigma)]. Lysates were
immunoprecipitated with anti-myc antibody (Roche). After ﬁve
washes with RIPA buffer, proteins were eluted and analyzed by
SDS–PAGE. PDX1 proteins were detected by ﬂuorography and
quantiﬁed in a Cyclone (Perkin–Elmer) phosphoimager storage
system.
2.13. Statistics
Data are given as means ±SE of three to ﬁve individual experi-
ments. Comparisons between means were performed using one-B
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3. Results
3.1. Ser-269 phosphorylation is regulated by glucose in living b-cells
(MIN6) and primary mouse islets
PDX1 Ser-269 was identiﬁed as a potential phosphorylation site
by mass spectrometry (Supplementary Fig. 1). We, therefore, ex-
plored the possibility that phosphorylation of PDX1 at Ser-269
may be regulated by glucose in living b-cells and, thus, may, at
least potentially, contribute to the regulation of PDX1 function
by the sugar. After treatment at low glucose concentrations
(3 mM) for 16 (MIN6 b-cells) or 1 h (islets), we further incubated
islets (Fig. 1A) or MIN6 b-cells (Fig. 1B) in medium containing
16.7 or 30 mM glucose, respectively, for varying times.
Examined in mouse islets, the nuclear content of phosphory-
lated Ser-269-PDX1 decreased following culture for 1 h at
16.7 mM glucose (Fig. 1A). In MIN6 b-cells, as early as 30 min after
the change in glucose concentration, cells maintained at 30 mM
glucose displayed a markedly lower degree of phosphorylation at-pS269-PDX-1
-PDX1
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repared in triplicate. Mean values from three independent experiments are shown.
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phosphorylation at Ser-269, during the subsequent 24 h.
3.2. HIPK2 phosphorylation of PDX1
Homeodomain interacting protein kinase 2 (HIPK2) was previ-
ously reported to phosphorylate the C-terminal domain of PDX1
at undeﬁned site(s) lying between amino acids 215 and 283 [17].
Since HIPK2 is a proline-directed kinase [17], and Ser-269 is adja-
cent to a proline residue, we investigated whether Ser-269 may be
phosphorylated by HIPK2 in vitro. This possibility was examined
using active HIPK2 and recombinant c-myc-tagged wild-type or
S269A PDX1 as substrates (Fig. 2). Wild-type PDX1 incorporated
[32P] proportionately with increasing concentration of HIPK2, in
agreement with the previous study [17] (Fig. 2A). Furthermore,
incorporation of [32P] into recombinant S269A PDX1 was substan-HIPK2 (pmol) 0 0.2 1 4
WT
0
PDX-1
PDX-1
B
HIPK2-P
PDX-1-P
HIPK2 (pmol) 0 0.2 1 4 0
WTPDX-1
PDX-1
A
control siRNA
scrambled siR
C D
siRN
0.0
0.1
0.2
0.3
0.4
0.5
H
IP
K2
 / 
cy
clo
ph
ilin
**
Fig. 2. Phosphorylation on Ser-269 by HIPK2 in vitro and in vivo. (A) 2 lg of recombinan
[c-32P] ATP for 30 min. Autoradiography shows the radiolabeled PDX1 and HIPK2. Coom
analyzed byWestern blot using indicated antibodies. MIN6 b-cells were cultured in the pr
using primers against mouse HIPK2 (C) or Western blotting with anti-phospho-Ser-269
independent experiments.tially decreased at all levels of HIPK2 activity tested when com-
pared to the wild-type factor (Fig. 2A). Parallel experiments
performed with non-radioactive ATP produced an immunoreactive
band at 46 kDa with anti-phospho-Ser-269 PDX1 antibody for
wild-type PDX1; while, as anticipated, a lack of immunoreactivity
was apparent after treatment of S269A PDX1 (Fig. 2B).
Whilst the increased signal detected with the anti-phospho-
Ser-269-speciﬁc PDX1 antibody in wild-type PDX1 conﬁrmed
HIPK2 mediated phosphorylation at this site, residual incorpora-
tion of phosphate into S269A PDX1 (Fig. 2A) suggested the exis-
tence of additional phosphorylation sites for this kinase. Indeed,
our mass spectrometry (Supplementary Fig. 1) identiﬁed a long
peptide, S211SGT214PSGGGGGEEPEQDCAVTSGEELLAVPPLPPPG-
GAVPPGVPAAVR that was also phosphorylated. Although the exact
site of phosphorylation on this peptide was not pursued further,
we noted a Thr-214 followed by a proline residue in this peptideα-pS269 PDX-1
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nases, including HIPK2.
Conﬁrming that Ser-269 phosphorylation occurs via HIPK2 in
living cells, MIN6 b-cells in which HIPK2 was silenced by
87.5 ± 1.0% after 72 h culture with siRNA (Fig. 2C), as assessed by
real-time PCR analysis (a commercial antibody that recognizes
endogenous HIPK2 not being available), had a 51 ± 0.2% decrease
in phospho-Ser-269 PDX1 content (Fig. 2D) after 24 h culture at
3 mM glucose.75
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Software Inc., San Jose, CA USA). Data points represent the mean ± SEM of three to four3.3. Phosphorylation on Ser-269 does not affect the stability of PDX1
We examined the half-life of the mutants by [35S] pulse chase
labeling experiments which revealed equal stability of phospho/
de-phospho-Ser-269 mimetic mutants of PDX1 (Fig. 3). We dem-
onstrated that wild-type c-myc-tagged-PDX1 has an estimated
half-life, when over expressed in MIN6 b-cells, of 5 h and 30 min
(±4). The turnover rates of S269A and S269E PDX1 were not signif-
icantly different from wild-type PDX1 (Fig. 3).75
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PDX1 in MIN6 b-cells
In order to determine whether de-phosphorylation at Ser-269
at elevated glucose concentrations may contribute to the nucleo-
plasmic accumulation of PDX1, MIN6 b-cells were transduced with
adenoviruses encoding c-myc-tagged wild-type, S269A or S269E
mutant forms of PDX1. Cells were then cultured at either 3 or
30 mM glucose. High glucose caused a signiﬁcant redistribution
both of the de-phosphomimetic mutant S269A PDX1 and wild-
type PDX1 from nuclear periphery to nucleoplasm (Fig. 4), consis-
tent with previous studies [18]. Thus, at 30 mM glucose wild-type
PDX1 was predominantly present in the nuclear region, as was the
de-phosphomimetic mutant, while the phospho-mimetic mutant
displayed a different localization (nuclear periphery) as compared
to wild-type PDX1.
4. Discussion
The principal aim of this study was to elucidate the molecular
mechanisms involved in the regulation by glucose and other
stimuli of the nuclear uptake, DNA binding and transactivation
capacities of PDX1, focusing on the potential role of protein
phosphorylation.3 mM Glucose
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Fig. 4. Ser-269 phosphorylation and PDX1 subnuclear localization (A) Immunocytoch
transduced with adenoviruses encoding for the indicated PDX1 molecules. Cells were cul
myc-tagged PDX1 was detected using anti-c-myc antibody (Roche) and Alexa-568 (Mo
captured using a Leica SP2 upright laser scanning confocal microscope (x63/1.32 oil-imm
and UV light. Images were analyzed off-line using VolocityTM 4.0 software. Each sam
localization predominantly at nuclear periphery is expressed as a percentage of the tot
shown.We demonstrate ﬁrstly throughmass spectrometry, and by sub-
sequent veriﬁcation with a phospho-speciﬁc antibody, that Ser-
269 in the C-terminal domain of PDX1 is phosphorylated in living
b-cells, consistent with recent ﬁndings [15]. We show here that
Ser-269 is de-phosphorylated in response to glucose and that
HIPK2 is capable of phosphorylating this residue both in vitro
and in vivo. Phosphorylation of the C-terminus of PDX1 in a region
encompassing Ser-269 by HIPK2 has previously been reported,
although the effects of glucose on this phenomenon were not de-
scribed [17]. We show that the degree of phosphorylation of
PDX1 at Ser-269 was decreased at elevated glucose concentrations.
A detailed analysis of the possible effects of phosphorylation at the
site using (de)phosphomimetic mutants failed to reveal any differ-
ences between the transactivation capacity of the wild-type pro-
tein compared to mutants bearing A or E in place of S269
(Supplementary Fig. 4). These observations, together with the anal-
ysis of the subnuclear localization of WT, S269A and S269E PDX1 in
MIN6 b-cells (Fig. 4), suggest that HIPK2 phosphorylation of PDX1
regulates PDX1 function via the regulation of its subnuclear local-
ization but not its transactivation potential.
HIPK2 regulates gene expression by phosphorylation of tran-
scription factors (including p53, Pax6, Myb) and accessory compo-
nents of the transcription machinery (among others p300, CtBP1)
([16] and references therein). A recent study reported that HIPK230 mM Glucose
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onic day e12 to e15 but that the expression becomes preferentially
conﬁned to pancreatic endocrine cells at later developmental
stages [17]. Moreover, HIPK2 was reportedly able to modulate pos-
itively the protein content and transcriptional activity of PDX1, and
directly phosphorylate the C-terminal portion of PDX1 [17]. Our
data now provide evidence that HIPK2 may be involved in the reg-
ulation of PDX1 function in living b-cells through phosphorylation
of Ser-269 and regulation of the subnuclear distribution of PDX1.
Boucher and colleagues [17] observed an increase of PDX1 tran-
scriptional activity and protein levels upon cotransfection of HEK
293 cells with a plasmid overexpressing HIPK2. By contrast, we
were not able in the present studies to detect major changes of
PDX1 transcriptional activity upon mutation of serine-269 to a
phospho- (glutamic acid) or de-phospho- (alanine) mimetic resi-
due, at least when examined in a heterologous expression system,
HEK293 cells (Supplementary Fig. 4). Importantly, in this cellular
context, we have not been able to observe effects of glucose on
the subnuclear localization of PDX1 (results not shown) suggesting
that such changes, as observed in the b-cell, may be the principal
route through which changes in Ser269 phosphorylation impact
on PDX1 function in the latter context. A further possibility is that
HIPK2 is able, as we observed in vitro, to phosphorylate PDX1 on
more than one site besides serine-269. In fact, the mass spectrom-
etry analysis that we performed on PDX1 overexpressed and
immunoprecipitated from clonal b-cells has conﬁrmed that pep-
tide 211SSGTPSGGGGGEEPEQDCAVTSGEELLAVPPLPPPGGAVPPGVP
AAVR258 bears at least one phosphate group as earlier observed
by Boucher and colleagues [17]. Threonine-214 in this peptide is
a likely candidate target for phosphorylation by HIPK2.
In contrast to earlier studies [15] we did not observe differences
in stability between wild-type and mutant (Ser-269) PDX1. One
signiﬁcant protocol difference between the present and earlier
studies is that we have analyzed more time points, allowing a more
precise determination of the half-life. Importantly, the calculated
half-life based on our protocol was shorter, at 5 h and 30 min
(±4 min), than the previously reported ‘‘approximately 8 h” [15].
Also, treatment of b-cells with 100 lg/ml cycloheximide, as under-
taken by Humphrey and colleagues, might have affected cellular
metabolism and hence protein turnover.
5. Conclusion
Our data provide evidence that serine 269 in mouse PDX1 is
phosphorylated in living pancreatic b-cells, as revealed through
the use of mass spectrometry and conﬁrmed by the generation of
a phosphoserine-speciﬁc antibody. We also show that this event
affects the subnuclear localization of PDX1 in b-cells.
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